SCHEMBL5651499

SCHEMBL5651499

CCOC(=O)c1sc2c(ccc(=O)n2Cc2ccc(Cl)cc2)c1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 2/20 0.51
ALDH1A1 P00352 4/20 0.47
MAPK1 P28482 1/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
CSF1R P07333 1/20 0.45
HPGD P15428 2/20 0.44
XBP1 P17861 1/20 0.44
MDM4 O15151 1/20 0.44
DHODH Q02127 1/20 0.44
KDR P35968 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651454 0.94 ALDH1A1 (0.54) MDM2ALDH1A1MAPK1MEN1KMT2A
SCHEMBL5650191 0.91 ALDH1A1 (0.47) MDM2ALDH1A1MAPK1CYP1A2CYP2C19
SCHEMBL5651409 0.87 ALDH1A1 (0.45) ALDH1A1MAPK1CYP1A2CYP2C19KDM4E
SCHEMBL5654426 0.85 ALDH1A1 (0.50) MDM2ALDH1A1MAPK1CYP1A2CYP2C19
SCHEMBL5648462 0.85 MAPK8 (0.51) ALDH1A1MAPK1KDM4EMEN1KMT2A
SCHEMBL5653013 0.85 GABRA1 (0.47) ALDH1A1MAPK1KDM4EMEN1KMT2A
SCHEMBL5652931 0.84 ACACB (0.53) ALDH1A1MAPK1KDM4EMEN1KMT2A
SCHEMBL5653004 0.83 ALDH1A1 (0.41) ALDH1A1MAPK1KDM4EMEN1KMT2A
SCHEMBL5648531 0.83 ALDH1A1 (0.47) MDM2ALDH1A1MAPK1CYP1A2CYP2C19
SCHEMBL5648783 0.82 LMNA (0.45) ALDH1A1MAPK1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 MDM2 2188/4885ALDH1A1 1498/4885MAPK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.